129 related articles for article (PubMed ID: 29746371)
1. Bortezomib-Associated Optic Atrophy in Two Patients With Multiple Myeloma.
Chacko JG; Behbehani R; Hundley KN; Al-Fanek Y
J Neuroophthalmol; 2018 Dec; 38(4):473-475. PubMed ID: 29746371
[No Abstract] [Full Text] [Related]
2. Nonglaucomatous Cupping: Fundus Photography and Spectral Domain Optical Coherence Tomography Imaging Features.
Aboobakar IF; Mettu P; El-Dairi MA
J Neuroophthalmol; 2016 Dec; 36(4):402-403. PubMed ID: 27468120
[TBL] [Abstract][Full Text] [Related]
3. Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse.
Reyal Y; Popat R; Cheesman S; Rismani A; D'Sa S; Rabin N; Yong K
Br J Haematol; 2017 May; 177(3):495-497. PubMed ID: 27062387
[No Abstract] [Full Text] [Related]
4. Sensorineural deafness: An uncommon irreversible adverse effect of bortezomib.
Anoop P; Patil CN; Joshi VS; Maurya P; Hosamani P
Indian J Cancer; 2016; 53(3):459. PubMed ID: 28244485
[No Abstract] [Full Text] [Related]
5. Corneal sub-basal neural damage pattern in multiple myeloma patients treated with bortezomib: an in vivo confocal study.
Cocito F; Ricciardelli G; Mangiacavalli S; Pompa A; Pochintesta L; Ferretti V; Ceccuzzi R; Cazzola M; Bianchi PE; Corso A
Leuk Lymphoma; 2015; 56(12):3440-1. PubMed ID: 25942384
[No Abstract] [Full Text] [Related]
6. Optical coherence tomography disc assessment in optic nerves with peripapillary atrophy.
Lai E; Wollstein G; Price LL; Paunescu LA; Stark PC; Fujimoto JG; Schuman JS
Ophthalmic Surg Lasers Imaging; 2003; 34(6):498-504. PubMed ID: 14620759
[TBL] [Abstract][Full Text] [Related]
7. Megalopapilla Simulating Pediatric Optic Atrophy.
Jung J; Brodsky MC
JAMA Ophthalmol; 2016 May; 134(5):e155037. PubMed ID: 27258605
[No Abstract] [Full Text] [Related]
8. Differentiating glaucomatous from nonglaucomatous optic atrophy.
Lee AG
Ophthalmology; 1999 May; 106(5):855. PubMed ID: 10328372
[No Abstract] [Full Text] [Related]
9. Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.
Reneau JC; Asante D; van Houten H; Sangaralingham LR; Buadi FK; Lerman A; Herrmann J
Am J Hematol; 2017 Feb; 92(2):E15-E17. PubMed ID: 27813147
[No Abstract] [Full Text] [Related]
10. Retinal Nerve Fiber Layer and Peripapillary Choroidal Thicknesses in Non-Glaucomatous Unilateral Optic Atrophy Compared with Unilateral Advanced Pseudoexfoliative Glaucoma.
Kucukevcilioglu M; Ayyildiz O; Aykas S; Gokce G; Koylu MT; Ozgonul C; Ozge G; Mumcuoglu T; Yumusak E
Curr Eye Res; 2017 Feb; 42(2):302-306. PubMed ID: 27348514
[TBL] [Abstract][Full Text] [Related]
11. Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort.
Grelaud A; Fourrier-Réglat A; Fitoussi O; Facon T; Jové J; Bénichou J; Robinson P; Marit G; Rouyer M; Moore N; Noize P;
Leuk Lymphoma; 2016; 57(6):1349-54. PubMed ID: 26397802
[TBL] [Abstract][Full Text] [Related]
12. [MAS-like lesions and SIADH caused by bortezomib in the treatment of multiple myeloma : three cases report and literature review].
Wang LL; Geng CY; Zhang YR; Wu Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):75-77. PubMed ID: 35231998
[No Abstract] [Full Text] [Related]
13. OCT and Band Atrophy Correlation.
Mehta JS; Plant GT
Ophthalmology; 2005 Nov; 112(11):2055-6; author reply 2056-7. PubMed ID: 16271326
[No Abstract] [Full Text] [Related]
14. Symmetrical Intertriginous and Flexural Exanthema due to Bortezomib (a Proteasome Inhibitor) Given for Myeloma.
Malissen N; Bourrain JL; Chiriac A; Montet A; Vincent L; Dereure O; Du-Thanh A
Acta Derm Venereol; 2016 Nov; 96(7):995-996. PubMed ID: 27001285
[No Abstract] [Full Text] [Related]
15. Bortezomib-Induced Muscle Toxicity in Multiple Myeloma.
Guglielmi V; Nowis D; Tinelli M; Malatesta M; Paoli L; Marini M; Manganotti P; Sadowski R; Wilczynski GM; Meneghini V; Tomelleri G; Vattemi G
J Neuropathol Exp Neurol; 2017 Jul; 76(7):620-630. PubMed ID: 28863457
[TBL] [Abstract][Full Text] [Related]
16. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.
Sezer O; Beksac M; Hajek R; Sucak G; Cagirgan S; Linkesch W; Meltem Akay O; Gülbas Z; Nahi H; Plesner T; Snowden JA; Timurağaoğlu A; Dechow T; Lang A; Tuğlular T; Drach J; Armbrecht G; Potamianou A; Couturier C; Olie RA; Feys C; Allietta N; Terpos E
Br J Haematol; 2017 Jul; 178(1):61-71. PubMed ID: 28382618
[TBL] [Abstract][Full Text] [Related]
17. Demyelinating polyradiculoneuritis in patients with multiple myeloma: the other side of bortezomib-induced neurotoxicity.
Gendreau S; Berzero G; Tafani C; Raynouard I; Ricard D; Malfuson JV; Viala K; Debs R; Houillier C; Diamanti L; Marchioni E; Lenglet T; Ouzegdouh M; Bihan K; Gilardin L; Psimaras D
Acta Oncol; 2020 Apr; 59(4):484-489. PubMed ID: 32122210
[No Abstract] [Full Text] [Related]
18. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
Laubach JP; Moslehi JJ; Francis SA; San Miguel JF; Sonneveld P; Orlowski RZ; Moreau P; Rosiñol L; Faber EA; Voorhees P; Mateos MV; Marquez L; Feng H; Desai A; van de Velde H; Elliott J; Shi H; Dow E; Jobanputra N; Esseltine DL; Niculescu L; Anderson KC; Lonial S; Richardson PG
Br J Haematol; 2017 Aug; 178(4):547-560. PubMed ID: 28466536
[TBL] [Abstract][Full Text] [Related]
19. Optical coherence tomography angiography in leber hereditary optic neuropathy.
Takayama K; Ito Y; Kaneko H; Kataoka K; Ra E; Terasaki H
Acta Ophthalmol; 2017 Jun; 95(4):e344-e345. PubMed ID: 27778481
[No Abstract] [Full Text] [Related]
20. Nonglaucomatous optic atrophy.
Golnik K
Neurol Clin; 2010 Aug; 28(3):631-40. PubMed ID: 20637993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
